The isoforms of the HP1 protein regulate the organization and structure of heterochromatin

November 21, 2017

Researchers from the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Àlex Vaquero, have elucidated the role of HP1 proteins in relation to chromatin structure and genome stability, distinguishing different functions based on the presence of different variants of this protein. The work, published in Cell Reports, was carried out in collaboration with other research groups in Europe and the United States.

Our genetic material is organized within the cell nucleus as chromatin, a structure consisting mainly of DNA molecules associated with histones and other proteins. Chromatin is found in two clearly differentiable states when the cell is not dividing: euchromatin (less condensed) and heterochromatin (more condensed). Heterochromatin protein 1 (HP1) is a structural component of heterochromatin that exists in three different variants or isoforms: HP1α, HP1β and HP1γ. Much of the activity of these isoforms seems to be redundant.

In a previous work published at the beginning of the year by the journal Epigenetics, Dr. Vaquero's team showed that, unlike previously thought, under conditions of oxidative stress (involved in diseases such as cancer, Parkinson's and Alzheimer's, as well as in aging), the three variants of HP1 play different roles maintaining stability and establishing different levels of chromatin compaction. Specifically, the three isoforms establish differential functional relationships with the methyltransferase Suv39h1, a key enzyme in epigenetic genome control.

In this new study published in Cell Reports, the regulatory role of HP1α, HP1β and HP1γ in relation to pericentric heterochromatin, that is, the one that delimits the centromere area or junction point between the sister chromatids in a chromosome, is studied. These regions play a key structural role in the genome, and their alteration is associated with genomic instability, chromosomal aberrations and human diseases such as cancer. In a series of experiments with mouse embryonic fibroblasts (MEFs), the researchers show that the specific loss of HP1α leads to a greater presence of the epigenetic marks H4K20me3 and H3K27me3, directly linked to the hypercompaction of chromatin; on the other hand, loss of HP1β leads to an increase in CTCF in the study area, a key transcription factor in the regulation of chromatin architecture.

Thus, based on the secondary interaction they generate with other proteins and enzymes, different HP1 proteins could play a differential role in the organization of chromatin domains. Quoting Dr. Vaquero, "HP1α would maintain, together with CTCF, the internal structure of peripheral heterochromatin by controlling the distribution of H4K20me3 and H3K27me3. This finding extends our current knowledge of the organization of the genome providing a new perspective regarding the role of HP1 isoforms and their functional relationship with heterochromatin structure and stability". Taking into account that alterations in pericentric heterochromatin have been related to defects in the cell cycle, DNA damage, chromosomal aberrations, cell death, cancer and aging, both basic research studies could potentially lead the way towards a better understanding of these processes linked to numerous diseases.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.